Effects of GV1001 on Language Dysfunction in Patients With Moderate-to-Severe Alzheimer's Disease: Post Hoc Analysis of Severe Impairment Battery Subscales.

Hyuk Sung Kwon Seong-Ho Koh Kyung Won Park Jee Hyang Jeong Hae Ri Na Chan-Nyoung Lee Young-Soon Yang Ae Young Lee Jae-Hong Lee Kyung-Won Park Hyun Jeong Han Byeong Chae Kim Jinse Park Jee-Young Lee Kyu Yong Lee Sangjae Kim

Published in: Dementia and neurocognitive disorders (2023)

Patients with moderate-to-severe AD receiving GV1001 had greater language benefits than those receiving placebo, as measured using the SIB language subscale.

Keyphrases

autism spectrum disorder
early onset
high intensity
oxidative stress
randomized controlled trial